Quick answer: Peptide therapy is an umbrella term for the clinical use of peptides, which are short chains of amino acids that act as signalling molecules. The term covers an enormous range, from FDA-approved medicines backed by large human trials to compounds whose evidence is animal or cell work only. A legitimate process involves a clinical evaluation, a medical history, laboratory testing where appropriate, and a prescriber who is willing to decline. Because the category is defined by chemistry rather than by evidence, the useful question is never whether peptide therapy works but which peptide, and on what evidence.
Peptide therapy is a category rather than a product, and the distinction matters more here than in almost any area of medicine people research alone. A peptide is a short chain of amino acids, shorter than a protein, which the body uses to carry signals between cells. Grouping compounds by that feature says nothing about what any one does or how well it has been studied.
What the term actually describes
Peptides function as messengers. Insulin is a peptide, and so are the hormones that tell the pituitary when to release growth hormone, the gut signals that register fullness after a meal, and many local messengers involved in tissue repair and immune regulation. Grouping all of them under one label resembles grouping every medication that happens to be a small molecule.
Clinical use of peptides is therefore not new, even though the marketing language around it is. Insulin has been a medicine for a century and several peptide drugs are among the most prescribed products in the country. What is new is the consumer facing packaging of a much wider set of compounds, many of which have never been through the process that produced those approved medicines. A useful starting point is this explanation of what peptides are and how they signal.
Who tends to look into it, and why
Men in their forties and early fifties make up a large share of the people researching this category, and what they describe is consistent. Recovery from training takes a day longer than it used to, sleep is lighter even when the hours are there, and the drive that used to be automatic now takes deliberate effort.
Most have already done the obvious work: sleep hygiene, resistance training, protein intake, bloodwork, sometimes testosterone therapy. Arriving at peptides is usually the end of a search rather than the start of one. Some of what people in that position are hoping for is age related change that no compound reverses, and some is a condition a proper workup would identify.
What a legitimate clinical process looks like
Evaluation comes first. A clinician takes a history covering symptoms, timeline, medications, prior therapies and relevant medical and family background, because several conditions that produce fatigue and poor recovery have nothing to do with peptides. Skipping the history in favour of a checkout page is the clearest sign that a service is selling rather than practising medicine.
Laboratory testing follows where it is clinically indicated, which is not always. Bloodwork can identify thyroid dysfunction, anaemia, glucose problems, low testosterone, kidney or liver issues and other explanations that change what should happen next. A fair question to any provider is what a given test would change about the plan.
The defining feature of a real clinical process is that the prescriber can say no. A provider who concludes that a compound is not appropriate, or that someone should not be managed remotely at all, is doing the job correctly. Practical checks are collected in this guide to verifying a peptide provider.
Why the evidence varies so widely across peptides
Evidence quality inside this category spans nearly the whole possible range. At one end sit peptide medicines approved after large randomised controlled trials in humans, with known effect sizes and published labelling. At the other sit compounds whose entire literature is cell culture and rodent work, occasionally from a single research group.
Preclinical results do not transfer reliably to humans, and that is not a technicality. Animal physiology differs, doses used in rodents often do not scale, and most compounds that look promising in preclinical work fail when tested properly in people. A peptide described as showing tissue repair effects in rats has demonstrated exactly that and nothing about outcomes in a human adult. This walkthrough of how to read the evidence behind a peptide claim covers the specific checks.
What the umbrella term hides
Marketing benefits from the ambiguity of the phrase. Placing an approved medicine and an unstudied compound under the same two word heading lets the credibility of the first quietly support the second, without any claim being made that could be challenged. Noticing that transfer is the most useful skill for reading this category.
Regulatory status is the other thing the umbrella obscures. Some peptides are approved drugs, some are compounded preparations that are not FDA-approved, some are sold only under research use only labelling that excludes human use, and some appear in supplements regulated as food. Four different legal and safety situations are described with one phrase, and the differences are set out in this overview of the legal status of peptides in the United States.
Questions worth asking before starting anything
Asking a provider what human evidence supports the specific compound filters quickly. A clinician who can describe the state of the literature, including where it is thin, is engaging with the actual question, while a reply that pivots to testimonials or user counts is answering something else.
Asking what happens if the compound does not help is the second question, because a real clinical relationship includes reassessment and a route to stopping. Asking who prepares the medication and what testing it undergoes is the third, and the difference from unregulated vials is explored in this comparison of research labelled peptides and prescribed ones.
Frequently Asked Questions
What is peptide therapy in simple terms?
Peptide therapy refers to the clinical use of short amino acid chains that act as signalling molecules, prescribed by a licensed clinician for a specific purpose. The term describes a category rather than a single therapy, so it covers approved medicines and barely studied compounds alike. What matters is which peptide is being discussed and what human evidence supports it.
Is peptide therapy FDA-approved?
Some peptides are FDA-approved medicines and many are not. Compounded peptide preparations are not FDA-approved products and are not the same as, nor a substitute for, approved ones, even when prepared by a licensed pharmacy. Regulatory status has to be checked compound by compound rather than assumed from the category label.
Who is peptide therapy for?
Peptide therapy is appropriate only when a licensed clinician evaluates a specific person and concludes that a specific compound is reasonable for them. People commonly investigate it for sleep quality, recovery and age related changes in energy, but interest is not the same as suitability. A prescriber may conclude that no therapy at all is the right answer.
Does peptide therapy require injections?
Most peptides used clinically are injected, because digestive enzymes break amino acid chains apart before they can be absorbed intact. Subcutaneous injection is the usual route for at home use, and the mechanics are described in this explanation of how peptide injections work.
How long does it take to know whether it is working?
Timelines differ by compound and by what is being tracked, and no honest general answer exists. A clinician should define in advance what would count as a response and when it will be reassessed. Individual results vary, and some people will see no meaningful change.
What is sermorelin, and where does it sit in this category?
Sermorelin is a peptide that acts on the pituitary as a growth hormone releasing hormone analog, prescribed after clinical evaluation and prepared by compounding pharmacies in the United States. Compounded sermorelin is not an FDA-approved product. Its position relative to other options is covered in this explanation of what sermorelin is and how it signals.
The honest summary
Peptide therapy is best understood as a shelf rather than a product. Everything on that shelf shares a chemical description and very little else, which means an argument for one peptide is not an argument for another. Anyone evaluating the category is really evaluating one compound at a time.
What a legitimate process offers a person is judgement rather than access. Evaluation, history, testing where indicated, a prescriber who can decline, a pharmacy whose preparations are tested, and a plan for reassessment are the parts that actually protect someone. Everhuman approaches this as an education problem first.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorganic & medicinal chemistry. 2018. PMID 28720325.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology. 2026. PMID 42395176.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID 41966639.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.